Adma Biologics Inc. Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 6 of 6 Posts
ADMA Biologics Announces Pricing Of Public Offering Of Common Stock
Article By: NASDAQ GlobeNewswire Saturday, June 9, 2018 2:00 AM EDT
ADMA Biologics, Inc. announced today the pricing of its previously announced underwritten public offering of 8,368,200 shares of its common stock at a public offering price of $4.78 per share.
In this article: ADMA
Read
ADMA Biologics: Almost Ready To Run Between The Toes Of Giants
Article By: Simon Daly Tuesday, March 6, 2018 10:27 PM EDT
ADMA’s lead product candidate has positive data, positioned for high unmet medical need. The burden of lifting regulatory hold is lower than might be perceived by investors at present.
In this article: ADMA
Read
ADMA Biologics Announces Pricing Of Follow-On Offering
Article By: NASDAQ GlobeNewswire Thursday, November 9, 2017 11:27 AM EDT
ADMA Biologics, Inc. today announced the pricing of an underwritten public offering of approximately 17.0 million shares of its common stock at a public offering price of $2.15 per share, representing gross proceeds of approximately $36.5 million.
In this article: ADMA
Read
Seven Biotech Names On The Upswing: 2016 Small-Cap Biotech Watchlist Update
Article By: The Life Sciences Report Wednesday, March 9, 2016 5:47 PM EDT
Biotech stocks—and the stock market in general—took a dive at the beginning of 2016, headed down on macroeconomic factors such as financial instability in China.
In this article: SGYP, CRMD, ORMP, SRNE, ARRY, PTIE, AGEN, GALE, PPHM, EVOK, ADMA, AKBA, KPTI, VSTM, AST, RXDX, AGTC, WVE, FATE, FLKS, PIRS, ABEO
Read
The 2016 Small-Cap Biotech Watchlist Debuts At The Biotech Showcase
Article By: The Life Sciences Report Wednesday, January 27, 2016 6:16 PM EDT
This may prove a challenging year for small-cap biotechs, but the five analysts who selected companies for inclusion on The Life Sciences Report's 2016 Small-Cap Biotech Watchlist believe these companies have a good producing value for investors.
In this article: AZN, NVO, SGYP, SNY, CRMD, ORMP, CMXHY, SRNE, ALNY, ARRY, INCY, IRWD, PTIE, REGN, VRTX, AGEN, GALE, GRFS, PPHM, EVOK, ADMA, AKBA, VSTM, AST, RXDX, AGTC, NK, WVE, FATE, FLKS
Read
Laidlaw's Yale Jen: Biotech 101 For Buyers And Sellers
Article By: The Life Sciences Report Friday, August 29, 2014 5:36 AM EDT
Former biotech consultant Yale Jen picked up a few tricks advising companies on their pipelines before he came to Wall Street as a sellside analyst.
In this article: GSK, PFE, ISIS, RPRX, BIIB, MSTX, ADMA, GLYC
Read
1 to 6 of 6 Posts